chlorthalidone has been researched along with Chronic Disease in 14 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective study of propranolol versus chlorthalidone has been performed in eleven patients with renal hypertension and one with essential hypertension." | 9.05 | Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension. ( Bachmann, H, 1984) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| "A prospective study of propranolol versus chlorthalidone has been performed in eleven patients with renal hypertension and one with essential hypertension." | 5.05 | Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension. ( Bachmann, H, 1984) |
| "During chronic chlorthalidone treatment of patients with essential hypertension, distal tubular sodium reabsorption is continuously inhibited." | 3.67 | The effect of converting enzyme inhibition on the enhanced proximal sodium reabsorption induced by chronic diuretic treatment in patients with essential hypertension. ( Dorhout Mees, EJ; Geyskes, GG; van Schaik, BA, 1987) |
| " In six patients with Bartter's syndrome, four with pseudo-Bartter's syndrome, and twenty with essential hypertension (EH) chronically treated with chlorthalidone, serum potassium (serum K+) and extracellular fluid volume (ECFV) were decreased, while plasma volume (PV) and blood volume (BV) were normal (see Table 1 for means, standard deviations, and levels of significance)." | 3.67 | Blood to interstitial fluid volume ratio in chronic hypokalaemic states. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; Hené, RJ; Koomans, HA; Roos, JC; Van Shaik, BA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (57.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakagawa, T | 1 |
| Johnson, RJ | 1 |
| Rahman, M | 2 |
| Ford, CE | 1 |
| Cutler, JA | 1 |
| Davis, BR | 2 |
| Piller, LB | 1 |
| Whelton, PK | 2 |
| Wright, JT | 2 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Haywood, LJ | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Oparil, S | 1 |
| Preston, R | 1 |
| Pressel, S | 1 |
| Nwachuku, C | 1 |
| Barzilay, J | 1 |
| Batuman, V | 1 |
| Eckfeldt, JH | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Henriquez, M | 1 |
| Kopyt, N | 1 |
| Louis, GT | 1 |
| Saklayen, M | 1 |
| Stanford, C | 1 |
| Walworth, C | 1 |
| Ward, H | 1 |
| Wiegmann, T | 1 |
| Bachmann, H | 1 |
| Baronchelli, A | 1 |
| Agosta, R | 1 |
| Verdecchia, P | 1 |
| Bichisao, E | 1 |
| Stornello, M | 1 |
| Valvo, EV | 1 |
| Scapellato, L | 1 |
| Labiós, M | 1 |
| Romero, M | 1 |
| Gabriel, F | 1 |
| Fuster, E | 1 |
| Tatay, E | 1 |
| Vallés, R | 1 |
| van Schaik, BA | 1 |
| Geyskes, GG | 2 |
| Dorhout Mees, EJ | 2 |
| Modai, D | 1 |
| Cohen, N | 1 |
| Weissgarten, J | 1 |
| Segal, B | 1 |
| Pik, A | 1 |
| Boer, P | 1 |
| Koomans, HA | 1 |
| Hené, RJ | 1 |
| Van Shaik, BA | 1 |
| Roos, JC | 1 |
| Sidorenko, BA | 1 |
| Kharchenko, VI | 1 |
| Tol'stykh, AN | 1 |
| Rawlins, MD | 1 |
| Sartorelli, E | 1 |
| Tomasini, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
1 review available for chlorthalidone and Chronic Disease
| Article | Year |
|---|---|
Variability in response to drugs.
Topics: Acute Disease; Acylation; Chlorthalidone; Chronic Disease; Depression; Diazoxide; Digoxin; Dose-Resp | 1974 |
5 trials available for chlorthalidone and Chronic Disease
| Article | Year |
|---|---|
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension.
Topics: Adolescent; Blood Pressure; Child; Child, Preschool; Chlorthalidone; Chronic Disease; Clinical Trial | 1984 |
[Advantages of a fixed association of oxprenolol-chlorthalidone, as opposed to chlorthalidone alone, in the treatment of chronic essential arterial hypertension].
Topics: Adult; Aged; Chlorthalidone; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Co | 1981 |
Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Chronic Disease; Diabetic Nephropathies; Diabetic Retinopa | 1991 |
8 other studies available for chlorthalidone and Chronic Disease
| Article | Year |
|---|---|
Hypertension: Is there a dark side to thiazide therapy for hypertension?
Topics: Chlorthalidone; Chronic Disease; Disease Progression; Diuretics; Humans; Hypertension; Kidney Diseas | 2010 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
[The blood rheology of diuretics].
Topics: Adult; Aged; Blood Pressure; Blood Viscosity; Chlorthalidone; Chronic Disease; Diuretics; Female; Hu | 1990 |
The effect of converting enzyme inhibition on the enhanced proximal sodium reabsorption induced by chronic diuretic treatment in patients with essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Chlorthalidone; C | 1987 |
Symptomatic renal artery stenosis superimposed on chronic glomerulonephritis.
Topics: Antihypertensive Agents; Cardiomegaly; Chlorthalidone; Chronic Disease; Creatinine; Furosemide; Glom | 1985 |
Blood to interstitial fluid volume ratio in chronic hypokalaemic states.
Topics: Bartter Syndrome; Blood Volume; Chlorthalidone; Chronic Disease; Extracellular Space; Female; Humans | 1985 |
[Use of saluretic preparation hygrotone for the treatment of patients with chronic circulatory insufficiency].
Topics: Adult; Aged; Ammonia; Chlorthalidone; Chronic Disease; Diuresis; Female; Glomerular Filtration Rate; | 1974 |
[Diuretic therapy with chlorthalidone in congestive heart failure caused by chronic cor pulmonale].
Topics: Adult; Aged; Chlorthalidone; Chronic Disease; Diuresis; Electrolytes; Heart Failure; Humans; Male; M | 1967 |